Role of synergy and immunostimulation in design of chemotherapy combinations: An analysis of doxorubicin and camptothecin.

ABSTRACT: Combination chemotherapy is often employed to improve therapeutic efficacies of drugs. However, traditional combination regimens often utilize drugs at or near-their maximum tolerated doses (MTDs), elevating the risk of dose-related toxicity and impeding their clinical success. Further, high doses of adjuvant or neoadjuvant chemotherapies can cause myeloablation, which compromises the immune response and hinders the efficacy of chemotherapy as well as accompanying treatments such as immunotherapy. Clinical outcomes can be improved if chemotherapy combinations are designed to reduce the overall doses without compromising their therapeutic efficacy. To this end, we investigated a combination of camptothecin (CPT) with doxorubicin (DOX) as a low-dose treatment option for breast cancer. DOX-CP

SUBMITTER: Pusuluri A 

PROVIDER: S-EPMC6584462 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature